Clinical Trials Logo
  1. Home
  2. Rhinitis, Allergic
  3. NCT04645979
  4. Details
NCT04645979 Clinical Trial

A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico

Rhinitis, Allergic Clinical Trial

Official title:
The Perception of Celestamine Treatment in Mexico: a Retrospective Assessment of Consumer Perception of Prior Celestamine Use

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04645979
Other study ID # 21614
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 11, 2020
Est. completion date November 27, 2020

Study information
Verified date May 2023
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute allergic rhinitis is a common allergic reaction to things like pollen or dust. It causes inflammation inside the nose, resulting in symptoms similar to the common cold. Allergic rhinitis is also known as hay fever. In this study, the researchers want to learn what participants think of betamethasone plus loratadine as a treatment for their acute allergic rhinitis. These participants will have used betamethasone plus loratadine as a treatment for their acute allergic rhinitis within the past two months. During the study, participants will complete an online questionnaire about their experience with betamethasone plus loratadine.

Recruitment information / eligibility
Status Completed
Enrollment 153
Est. completion date November 27, 2020
Est. primary completion date November 27, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria: - Participants who used betamethasone plus loratadine within the previous 2 months for the treatment of acute episodes of allergic rhinitis - Participants allowing to use the data for research and marketing purposes as well as talking to authorities - Participants allowing us to use the pseudo-randomized individual data for further data analysis - Able to read and understand the language of the online questionnaire Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Online survey
Participants will be invited to complete an online questionnaire about their experience of product use.

Locations
Country Name City State
Mexico Many locations Multiple Locations

Sponsors (1)
Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Mexico, 

Outcome
Type Measure Description Time frame Safety issue
Primary Experience with betamethasone plus loratadine via an online questionnaire Participants' experiences with betamethasone plus loratadine used under real life conditions. 2 months
See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT02486159 - The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture N/A
Completed NCT00770315 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Phase 3
Completed NCT00771160 - MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED) Phase 3
Completed NCT00834119 - Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270) Phase 4
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT03758456 - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human Phase 1
Completed NCT05122143 - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers N/A
Completed NCT05901532 - Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis Phase 2
Terminated NCT02722083 - Exploratory Study for Allergy Relief Onset Phase 2
Recruiting NCT05656482 - Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT06436534 - Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis N/A
Recruiting NCT05922176 - Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
Completed NCT02679105 - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy Phase 2/Phase 3
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A

External Links